Recommendations for Nanomedicine Human Subjects Research Oversight: An Evolutionary Approach for an Emerging Field

Leili Fatehi, Susan M. Wolf, Jeffrey Mccullough, Ralph Hall, Frances Lawrenz, Jeffrey P. Kahn, Cortney Jones, Stephen A. Campbell, Rebecca S. Dresser, Arthur G. Erdman, Christy L. Haynes, Robert A. Hoerr, Linda F. Hogle, Moira A. Keane, George Khushf, Nancy M P King, Efrosini Kokkoli, Gary Marchant, Andrew Maynard, Martin PhilbertGurumurthy Ramachandran, Ronald A. Siegel, Samuel Wickline

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

The nanomedicine field is fast evolving toward complex, "active," and interactive formulations. Like many emerging technologies, nanomedicine raises questions of how human subjects research (HSR) should be conducted and the adequacy of current oversight, as well as how to integrate concerns over occupational, bystander, and environmental exposures. The history of oversight for HSR investigating emerging technologies is a patchwork quilt without systematic justification of when ordinary oversight for HSR is enough versus when added oversight is warranted. Nanomedicine HSR provides an occasion to think systematically about appropriate oversight, especially early in the evolution of a technology, when hazard and risk information may remain incomplete. This paper presents the consensus recommendations of a multidisciplinary, NIH-funded project group, to ensure a science-based and ethically informed approach to HSR issues in nanomedicine, and to integrate HSR analysis with analysis of occupational, bystander, and environmental concerns. We recommend creating two bodies, an interagency Human Subjects Research in Nanomedicine (HSR/N) Working Group and a Secretary's Advisory Committee on Nanomedicine (SAC/N). HSR/N and SAC/N should perform 3 primary functions: (1) analysis of the attributes and subsets of nanomedicine interventions that raise HSR challenges and current gaps in oversight; (2) providing advice to relevant agencies and institutional bodies on the HSR issues, as well as federal and federal-institutional coordination; and (3) gathering and analyzing information on HSR issues as they emerge in nanomedicine. HSR/N and SAC/N will create a home for HSR analysis and coordination in DHHS (the key agency for relevant HSR oversight), optimize federal and institutional approaches, and allow HSR review to evolve with greater knowledge about nanomedicine interventions and greater clarity about attributes of concern.

Original languageEnglish (US)
Pages (from-to)716-750
Number of pages35
JournalJournal of Law, Medicine and Ethics
Volume40
Issue number4
DOIs
StatePublished - Dec 2012

Fingerprint

Nanomedicine
Research
Advisory Committees
Technology
Human Body
United States Dept. of Health and Human Services
Environmental Exposure
Occupational Exposure

ASJC Scopus subject areas

  • Health Policy
  • Issues, ethics and legal aspects

Cite this

Recommendations for Nanomedicine Human Subjects Research Oversight : An Evolutionary Approach for an Emerging Field. / Fatehi, Leili; Wolf, Susan M.; Mccullough, Jeffrey; Hall, Ralph; Lawrenz, Frances; Kahn, Jeffrey P.; Jones, Cortney; Campbell, Stephen A.; Dresser, Rebecca S.; Erdman, Arthur G.; Haynes, Christy L.; Hoerr, Robert A.; Hogle, Linda F.; Keane, Moira A.; Khushf, George; King, Nancy M P; Kokkoli, Efrosini; Marchant, Gary; Maynard, Andrew; Philbert, Martin; Ramachandran, Gurumurthy; Siegel, Ronald A.; Wickline, Samuel.

In: Journal of Law, Medicine and Ethics, Vol. 40, No. 4, 12.2012, p. 716-750.

Research output: Contribution to journalArticle

Fatehi, L, Wolf, SM, Mccullough, J, Hall, R, Lawrenz, F, Kahn, JP, Jones, C, Campbell, SA, Dresser, RS, Erdman, AG, Haynes, CL, Hoerr, RA, Hogle, LF, Keane, MA, Khushf, G, King, NMP, Kokkoli, E, Marchant, G, Maynard, A, Philbert, M, Ramachandran, G, Siegel, RA & Wickline, S 2012, 'Recommendations for Nanomedicine Human Subjects Research Oversight: An Evolutionary Approach for an Emerging Field', Journal of Law, Medicine and Ethics, vol. 40, no. 4, pp. 716-750. https://doi.org/10.1111/j.1748-720X.2012.00703.x
Fatehi, Leili ; Wolf, Susan M. ; Mccullough, Jeffrey ; Hall, Ralph ; Lawrenz, Frances ; Kahn, Jeffrey P. ; Jones, Cortney ; Campbell, Stephen A. ; Dresser, Rebecca S. ; Erdman, Arthur G. ; Haynes, Christy L. ; Hoerr, Robert A. ; Hogle, Linda F. ; Keane, Moira A. ; Khushf, George ; King, Nancy M P ; Kokkoli, Efrosini ; Marchant, Gary ; Maynard, Andrew ; Philbert, Martin ; Ramachandran, Gurumurthy ; Siegel, Ronald A. ; Wickline, Samuel. / Recommendations for Nanomedicine Human Subjects Research Oversight : An Evolutionary Approach for an Emerging Field. In: Journal of Law, Medicine and Ethics. 2012 ; Vol. 40, No. 4. pp. 716-750.
@article{3c04b7f5959b4a878389b12331bbcc18,
title = "Recommendations for Nanomedicine Human Subjects Research Oversight: An Evolutionary Approach for an Emerging Field",
abstract = "The nanomedicine field is fast evolving toward complex, {"}active,{"} and interactive formulations. Like many emerging technologies, nanomedicine raises questions of how human subjects research (HSR) should be conducted and the adequacy of current oversight, as well as how to integrate concerns over occupational, bystander, and environmental exposures. The history of oversight for HSR investigating emerging technologies is a patchwork quilt without systematic justification of when ordinary oversight for HSR is enough versus when added oversight is warranted. Nanomedicine HSR provides an occasion to think systematically about appropriate oversight, especially early in the evolution of a technology, when hazard and risk information may remain incomplete. This paper presents the consensus recommendations of a multidisciplinary, NIH-funded project group, to ensure a science-based and ethically informed approach to HSR issues in nanomedicine, and to integrate HSR analysis with analysis of occupational, bystander, and environmental concerns. We recommend creating two bodies, an interagency Human Subjects Research in Nanomedicine (HSR/N) Working Group and a Secretary's Advisory Committee on Nanomedicine (SAC/N). HSR/N and SAC/N should perform 3 primary functions: (1) analysis of the attributes and subsets of nanomedicine interventions that raise HSR challenges and current gaps in oversight; (2) providing advice to relevant agencies and institutional bodies on the HSR issues, as well as federal and federal-institutional coordination; and (3) gathering and analyzing information on HSR issues as they emerge in nanomedicine. HSR/N and SAC/N will create a home for HSR analysis and coordination in DHHS (the key agency for relevant HSR oversight), optimize federal and institutional approaches, and allow HSR review to evolve with greater knowledge about nanomedicine interventions and greater clarity about attributes of concern.",
author = "Leili Fatehi and Wolf, {Susan M.} and Jeffrey Mccullough and Ralph Hall and Frances Lawrenz and Kahn, {Jeffrey P.} and Cortney Jones and Campbell, {Stephen A.} and Dresser, {Rebecca S.} and Erdman, {Arthur G.} and Haynes, {Christy L.} and Hoerr, {Robert A.} and Hogle, {Linda F.} and Keane, {Moira A.} and George Khushf and King, {Nancy M P} and Efrosini Kokkoli and Gary Marchant and Andrew Maynard and Martin Philbert and Gurumurthy Ramachandran and Siegel, {Ronald A.} and Samuel Wickline",
year = "2012",
month = "12",
doi = "10.1111/j.1748-720X.2012.00703.x",
language = "English (US)",
volume = "40",
pages = "716--750",
journal = "Journal of Law, Medicine and Ethics",
issn = "1073-1105",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Recommendations for Nanomedicine Human Subjects Research Oversight

T2 - An Evolutionary Approach for an Emerging Field

AU - Fatehi, Leili

AU - Wolf, Susan M.

AU - Mccullough, Jeffrey

AU - Hall, Ralph

AU - Lawrenz, Frances

AU - Kahn, Jeffrey P.

AU - Jones, Cortney

AU - Campbell, Stephen A.

AU - Dresser, Rebecca S.

AU - Erdman, Arthur G.

AU - Haynes, Christy L.

AU - Hoerr, Robert A.

AU - Hogle, Linda F.

AU - Keane, Moira A.

AU - Khushf, George

AU - King, Nancy M P

AU - Kokkoli, Efrosini

AU - Marchant, Gary

AU - Maynard, Andrew

AU - Philbert, Martin

AU - Ramachandran, Gurumurthy

AU - Siegel, Ronald A.

AU - Wickline, Samuel

PY - 2012/12

Y1 - 2012/12

N2 - The nanomedicine field is fast evolving toward complex, "active," and interactive formulations. Like many emerging technologies, nanomedicine raises questions of how human subjects research (HSR) should be conducted and the adequacy of current oversight, as well as how to integrate concerns over occupational, bystander, and environmental exposures. The history of oversight for HSR investigating emerging technologies is a patchwork quilt without systematic justification of when ordinary oversight for HSR is enough versus when added oversight is warranted. Nanomedicine HSR provides an occasion to think systematically about appropriate oversight, especially early in the evolution of a technology, when hazard and risk information may remain incomplete. This paper presents the consensus recommendations of a multidisciplinary, NIH-funded project group, to ensure a science-based and ethically informed approach to HSR issues in nanomedicine, and to integrate HSR analysis with analysis of occupational, bystander, and environmental concerns. We recommend creating two bodies, an interagency Human Subjects Research in Nanomedicine (HSR/N) Working Group and a Secretary's Advisory Committee on Nanomedicine (SAC/N). HSR/N and SAC/N should perform 3 primary functions: (1) analysis of the attributes and subsets of nanomedicine interventions that raise HSR challenges and current gaps in oversight; (2) providing advice to relevant agencies and institutional bodies on the HSR issues, as well as federal and federal-institutional coordination; and (3) gathering and analyzing information on HSR issues as they emerge in nanomedicine. HSR/N and SAC/N will create a home for HSR analysis and coordination in DHHS (the key agency for relevant HSR oversight), optimize federal and institutional approaches, and allow HSR review to evolve with greater knowledge about nanomedicine interventions and greater clarity about attributes of concern.

AB - The nanomedicine field is fast evolving toward complex, "active," and interactive formulations. Like many emerging technologies, nanomedicine raises questions of how human subjects research (HSR) should be conducted and the adequacy of current oversight, as well as how to integrate concerns over occupational, bystander, and environmental exposures. The history of oversight for HSR investigating emerging technologies is a patchwork quilt without systematic justification of when ordinary oversight for HSR is enough versus when added oversight is warranted. Nanomedicine HSR provides an occasion to think systematically about appropriate oversight, especially early in the evolution of a technology, when hazard and risk information may remain incomplete. This paper presents the consensus recommendations of a multidisciplinary, NIH-funded project group, to ensure a science-based and ethically informed approach to HSR issues in nanomedicine, and to integrate HSR analysis with analysis of occupational, bystander, and environmental concerns. We recommend creating two bodies, an interagency Human Subjects Research in Nanomedicine (HSR/N) Working Group and a Secretary's Advisory Committee on Nanomedicine (SAC/N). HSR/N and SAC/N should perform 3 primary functions: (1) analysis of the attributes and subsets of nanomedicine interventions that raise HSR challenges and current gaps in oversight; (2) providing advice to relevant agencies and institutional bodies on the HSR issues, as well as federal and federal-institutional coordination; and (3) gathering and analyzing information on HSR issues as they emerge in nanomedicine. HSR/N and SAC/N will create a home for HSR analysis and coordination in DHHS (the key agency for relevant HSR oversight), optimize federal and institutional approaches, and allow HSR review to evolve with greater knowledge about nanomedicine interventions and greater clarity about attributes of concern.

UR - http://www.scopus.com/inward/record.url?scp=84872146492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872146492&partnerID=8YFLogxK

U2 - 10.1111/j.1748-720X.2012.00703.x

DO - 10.1111/j.1748-720X.2012.00703.x

M3 - Article

C2 - 23289677

AN - SCOPUS:84872146492

VL - 40

SP - 716

EP - 750

JO - Journal of Law, Medicine and Ethics

JF - Journal of Law, Medicine and Ethics

SN - 1073-1105

IS - 4

ER -